Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran
Open Access
- 1 November 2011
- journal article
- Published by Taylor & Francis Ltd in ClinicoEconomics and Outcomes Research
- Vol. 3, 207-12
- https://doi.org/10.2147/ceor.s25909
Abstract
Peer reviewed article authored by (Rasekh HR, Imani A, Karimi M, Golestani M). Read article or submit your manuscript for publishing.This publication has 35 references indexed in Scilit:
- International workshop on immune tolerance induction: consensus recommendations1Haemophilia, 2007
- A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) StudyBlood, 2006
- Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitorsHaemophilia, 2005
- The economic impact of factor VIII inhibitors in patients with haemophiliaHaemophilia, 2004
- Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.2001
- Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper.2000
- The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in CanadaHaemophilia, 1999
- Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerationsHaemophilia, 1999
- Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study GroupTransfusion, 1990
- Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIIIThe New England Journal of Medicine, 1988